Developing differentiated medicines

for devastating diseases including intractable cancers, lymphatic and GI diseases, CNS disorders and inflammatory and immunological diseases

Focus on the Brain Immune Gut (BIG) Axis

24 products and product candidates

13 are clinical stage

2 granted FDA clearance

Relationships with multiple major pharma companies or their investment arms

Team of world-class scientists and industry leaders

PureTech's Components of Value


Learn more about our unique discovery process

Wholly Owned Pipeline

Our programs
Phase 1
Phase 2
Phase 3
Lymphatic flow disorders, incl. lymphedema
Initiation of POC study in 2020
COVID-19 post-recovery respiratory complications
Initiation of POC study in Q3 2020
Other fibrotic & inflammatory disorders
Anti-Galectin-9 MAb
Solid tumors
IND and initiation of Ph1 study in 2020
Anti-Delta-1 MAb
Solid tumors
Anti-Delta-1 MAb
GI autoimmunity
Lymphatic Targeting Chemistry Platform
Orphan & other
neurological indications
Oral Biotherapeutics Platform
Meningeal Lymphatics Platform

Cash at Puretech Parent Level

Founded Entities

1. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly.

3. PureTech Level Pro-forma Cash Reserves is an alternative performance measure (APM) which includes the PureTech Level Cash Reserves of $120.6 million and the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares. PureTech Pro-forma Cash Reserves is therefore considered to be more representative of the Corporate’s cash available for the year 2020 and beyond to advance product candidates within the full breadth of its operations.

4. PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $112.0 million for the year ended 2019 and the internal pipeline of $8.6 million for the year ended 2019, all of which are wholly-owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities. The balance excludes the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares.

5. 44.5 million in proceeds from the 22 May 2020 sale of 555.5 thousand Karuna common shares.

Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Science: The Gut’s Clostridium Cocktail
Press releases
PureTech to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference


Press releases
Notice of Half-Yearly Results


Press releases
PureTech Founded Entity Vor Biopharma Appoints David Lubner to its Board of Directors